China's National Medical Products Administration approved its first treatment that specifically targets COVID-19. It uses a cocktail of two antibodies developed in China. Professor Zhang Linqi of Tsinghua University led the research team. Professor Zhang calls it cocktail therapy developed by selecting two monoclonal antibodies that inhibit the virus from infecting healthy cells. He talks about the drug's effectiveness.